<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371589">
  <stage>Registered</stage>
  <submitdate>2/10/2016</submitdate>
  <approvaldate>8/11/2016</approvaldate>
  <actrnumber>ACTRN12616001541493p</actrnumber>
  <trial_identification>
    <studytitle>A comparison of plasma levobupivacaine concentrations following thoracic epidural analgesia (TEA) and intrapleural analgesia (IPA).</studytitle>
    <scientifictitle>A comparison of plasma levobupivacaine concentrations following thoracic epidural analgesia and intrapleural analgesia - a comparison of pharmacokinetics of levobupivacaine, analgesic effectiveness and complication rate in pacient undergoing thoracotomy.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>open thoracic surgery</healthcondition>
    <healthcondition>epidural analgesics</healthcondition>
    <healthcondition>intrapleural analgesics</healthcondition>
    <healthcondition>levobupivacaine pharmacokinetics</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1. Thoracotomy - diagnostic or therapeutic.anterolateral thoracotomy.

2. Introduction of either thoracic epidural analgesia (TEA) or intrapleural analgesia (IPA)- epidural or intrapleural cathether insertion.
TEA group.
Insertion of epidural catheter prior surgery using midline or paramedian approach ( level Th2-Th7 depending on surgical procedure). Surgery under general anaesthesia. Immediatelly after thoracotomy closure, bolus of 0,25% 0,25ml/kg levobupivacaine (Chirocaine, AbbVie Ltd., Wanwall, UK) will be given into the epi-catheter.
IPA group.
Surgery under general anaesthesia (the same type as in TEA group). Insertion of intrapleural cathether placement into a pleural cavity before thoracotomy closure under direct visual control of a surgeon. Immediatelly after thoracotomy closure, bolus of 0,25% 0,25ml/kg levobupivacaine (Chirocaine, AbbVie Ltd., Wanwall, UK) will be given into the  intrapleural catheter.</interventions>
    <comparator>Comparison between TEA and IPA group.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Measuring of levobupivacaine plasma concentration in 30, 60 and 120 minutes after levobupivacaine bolus (dose/kg) application. Mean maximum plasma concentration (Cmax) and mean time to reach Cmax (Tmax) will be reported.</outcome>
      <timepoint>Levobupivacaine plasma levels in 30,60 and 120 minutes after application.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Visual analogue scale (VAS) evaluation of postoperative pain.</outcome>
      <timepoint>Evaluation of VAS in 1, 2, 6, 12 and 24 hours.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mobility score (AMPAC) evaluation.</outcome>
      <timepoint>AMPAC evaluation in 1, 2, 6, 12 and 24 hours after the surgery.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Necessity of pharmacological support of circulation (noradrenalin administration and dosing to maintain mean arterial pressure between 70-85mmHg).
Assessed by review of the medical charts.</outcome>
      <timepoint>Evaluation in 1, 2, 6, 12 and 24 hours after the surgery.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Complications related to local anaesthetic toxicity:
O - none
C - cardiac - new heart rhythm pathologies 
N - neurological - signs of local anaesthetic toxicity - blurred vision, metal taste, seizures, coma
Assessed by review of the medical charts.  </outcome>
      <timepoint>Evaluation in 1, 2, 6, 12 and 24 hours after the surgery.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. elective surgery (thoracotomy)
2. ASA status I-IV</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Age &lt; 18 years
2. Acute or emergent surgery
3. Contraindication of both TEA and IPA method
4. Refusal of both TEA and IPA by a patient.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence>Irrelevant</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods>A prospective study.
3 venous blood samples will be obtained at 30, 60 and 120 minutes after injection of studied drug (levobupivacaine).
44 patients will be included (22 TEA, 22 IPA) with an effect size of 0,05 and a statistical power of 0,8.
To determine the maximum plasma concentration (Cmax) and time-to-reach Cmax (Tmax) in each group, a non-linear regression analysis will be performed using a two-compartment model of measured plasma concentrations.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/12/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/05/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>44</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/08/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Czech Rep/Prague</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>General University Hospital in Prague</primarysponsorname>
    <primarysponsoraddress>U Nemocnice 2
Prague 2
12800</primarysponsoraddress>
    <primarysponsorcountry>Czech Republic</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>General University Hospital in Prague</fundingname>
      <fundingaddress>U Nemocnice 2, Prague 2, 12800</fundingaddress>
      <fundingcountry>Czech Republic</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A comparison ot two groups with either TEA or IPA after thoracotomy. The aim of the prospective study is to compare a blood concentrations of levobupivacaine 30, 60 and 120 minutes after an injection. Futher, possible side effects of levobupivacaine as well as analgesic effectivness (VAS, AM-PAC score) will be monitored and related to measured blood levobupivacaine concentrations.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Submitted, not yet approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics committee of General University Hospital, Prague</ethicname>
      <ethicaddress>Na Bojisti 1
Prague 2
128 00</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>5/09/2016</ethicsubmitdate>
      <ethiccountry>Czech Republic</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jan Matek</name>
      <address>1st Surgical Department
General University Hospital
U nemocnice 2
Prague 2
128 00</address>
      <phone>+420224962215</phone>
      <fax />
      <email>jan.matek@vfn.cz</email>
      <country>Czech Republic</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Pavel Michalek</name>
      <address>Dept of Anesthesia and Intensive Care Medicine
General University Hospital
U nemocnice 2
Prague 2
128 00</address>
      <phone>+420224962118</phone>
      <fax />
      <email>pavel.michalek@vfn.cz</email>
      <country>Czech Republic</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Pavel Michalek</name>
      <address>Dept of Anesthesia and Intensive Care Medicine
General University Hospital
U nemocnice 2
Prague 2
128 00</address>
      <phone>+420224962118</phone>
      <fax />
      <email>pavel.michalek@vfn.cz</email>
      <country>Czech Republic</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Pavel Michalek</name>
      <address>Dept of Anesthesia and Intensive Care Medicine
General University Hospital
U nemocnice 2
Prague 2
128 00</address>
      <phone>+420224962118</phone>
      <fax />
      <email>pavel.michalek@vfn.cz</email>
      <country>Czech Republic</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>